Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $35.00

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eleven have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $35.00.

DYN has been the subject of a number of research reports. Sanford C. Bernstein raised their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Morgan Stanley decreased their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Finally, Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th.

Dyne Therapeutics Trading Up 1.3%

Shares of DYN opened at $18.19 on Monday. The business’s 50-day moving average price is $18.27 and its 200 day moving average price is $18.18. The stock has a market capitalization of $3.01 billion, a P/E ratio of -5.65 and a beta of 1.09. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) EPS. Analysts expect that Dyne Therapeutics will post -3 earnings per share for the current year.

Insider Activity

In other Dyne Therapeutics news, Director Brian S. Posner acquired 2,000 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was purchased at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the transaction, the director owned 24,500 shares of the company’s stock, valued at $415,030. The trade was a 8.89% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jason P. Rhodes sold 83,219 shares of Dyne Therapeutics stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total value of $1,512,921.42. Following the sale, the director owned 7,962 shares of the company’s stock, valued at approximately $144,749.16. This represents a 91.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders acquired 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. 9.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently made changes to their positions in DYN. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter valued at about $26,000. Strs Ohio acquired a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after buying an additional 1,109 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $84,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.